NextCell Presents Quarterly Report

April 23, 2025

NextCell Pharma AB ("NextCell" or the "Company") invites investors, analysts and media to an investor presentation in conjunction with the publication of the Company's second interim report for the 2024/2025 financial year, on Thursday, 25 April 2025.

CEO Mathias Svahn will present the Company, the report, and the results from the subgroup analysis published on 7 April 2025. The Company’s subsidiaries, Cellaviva and QVance, will also be presented by their respective CEOs: Sofie Falk Jansson (Cellaviva) and Lindsay Davies (QVance). Attendees, both on-site and online, will have the opportunity to ask questions. The presentation will be available for on-demand streaming.

Time: Friday, 25 April 2025, at 2:00 PM

Venue: Redeye, Mäster Samuelsgatan 42, Stockholm, Sweden

Registration (for on-site attendance): Please register by email to events@redeye.se

Webcast (no pre-registration required): Please follow this link:

https://www.redeye.se/events/1095576/business-update-nextcell-pharma

For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Patrik Fagerholm, CFO

Tel: 0+46 8-735 5595

E-mail: info@nextcellpharma.com

Website: www.nextcellpharma.com

LinkedIn: https://www.linkedin.com/company/15255207/

Twitter: https://twitter.com/NextCellPharma

For information about Cellaviva, please contact:

Sofie Falk Jansson, CEO

Tel: 08-735 2010

E-mail: info@cellaviva.se

Website: www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige

Twitter: https://www.instagram.com/cellaviva/

Certified Adviser
The company's shares are listed on the Nasdaq First North Growth Market.
RedEye AB is assigned as Certified Adviser.

About NextCell Pharma AB
NextCell is a cell therapy company in Phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes. NextCell owns Cellaviva AB, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use. NextCell also owns QVance which will offer quality control analytics for advanced therapy developers. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology.

Download attachment Read full press release on Cision (external link)

2024-02-27

NextCell Pharma’s updated growth strategy

NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company has decided to implement strategic changes. The new strategic direction means, amongst other things, that Cellaviva will become a wholly owned subsidiary and that the company's GMP facility will have new sources of revenue. The strategic changes will also result in cost savings as a result of staff reduction.

Read more Read more

2024-02-14

NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy

Today Wednesday on February 14th at 10.30 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye.

Read more Read more

2024-01-25

NextCell publishes its Interim Report 1 2023/2024

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2023 – November 30, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2024-01-24

Updates regarding NextCell’s Clinical Trials with ProTrans

NextCell Pharma has several ongoing clinical trials with ProTrans. The largest ongoing study ProTrans Young, which includes 66 patients, is progressing well. All 30 patients in the older age group have been recruited and will be treated with ProTrans. In the long-term follow-up studies ProTrans-Obs and ProTrans-Repeat the first diabetes patients have now completed the studies after five years of follow-up.

Read more Read more

2023-12-13

NextCell Pharma has compiled a Q&A section

NextCell Pharma AB ("NextCell" or the "Company") has compiled questions from the company’s stakeholders in a Q&A section. The questions and answers can be accessed via the link below.

Read more Read more

2023-11-06

Repeated treatment with ProTrans is immunologically safe

NextCell Pharma AB ("NextCell" or the "Company") today announces that multiple treatments with ProTrans cell therapy does not induce donor specific antibodies in type-1 diabetes patients. A detailed analysis of how the immune system reacts to infusion of ProTrans cells show that treatment can be given to any adult type 1 diabetic, irrespective of pre-existing HLA antibodies.

Read more Read more

2023-10-26

NextCell publishes its Year-End Report 2022/2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2022 – August 31, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Read more Read more

2023-10-10

NextCell signs an agreement for a new tissue product

NextCell Pharma AB (“NextCell” or “the company”) announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.

Read more Read more